Enzyme therapy for Gaucher disease: The first 5 years

Blood Reviews

Volumn 12, Issue 2, 1998, Pages 115-133

  Grabowski, G A ^a   Leslie, N ^a   Wenstrup, R ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE;

DISEASE COURSE; ENZYME REPLACEMENT; ENZYME THERAPY; GAUCHER DISEASE; HUMAN; ONSET AGE; PRIORITY JOURNAL; REVIEW; SPLEEN;

EID: 0031868229     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(98)90023-6     Document Type: Article

References (100)

1. Gaucher PCE. De l'epithelioma primitif de la rate, hypertrophie idiopathique del la rate san leucemie. MD Thesis, Paris, 1882.
2. Mandelbaum FS, Downey H. The histopathology and biology of Gauchers disease (large-cell splenomegaly). Folia Haemal 1916; 20: 139.
3. Rusca CL. Sul morbo del Gaucher. Haematologica (Pravia) 1921; 2: 441.
4. Brady RO, Kanfer JN. Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 1965; 18: 221.
5. Beutler E, Grabowski GA. Glucosylceramide lipidoses: Gaucher disease. In: Scriver CR, Beaudet al, Sly WS, Valle D (eds). The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995, 2641.
6. Erikson A. Gaucher disease - Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand Suppl 1986; 326: 1.
7. Koerner TA, Cary LW. Li S, Li Y. Carbon 13 NMR spectroscopy of a cerebrosides: proof of the β-pyranosyl structure of D-glucosylceramide. J Biol Chem 1979; 254: 2326.
8. Nilsson O, Grabowski GA, Ludman MD, Desnick RJ, Svennerholm L. Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants. Clin Genet 1985; 27: 443.
9. Kattlove HE, Williams JC, Gaynor E, Spivack M, Bradley RM, Brady RO. Gaucher cells in chronic myelocytic leukemia: an acquired abnormality. Blood 1969; 33: 379.
10. Lee RE. The fine structure of the cerebroside occurring in Gaucher's disease. Proc Natl Acad Sci USA 1968; 61: 484.
11. Lee RE, Worthington CR, Glew RH. The bilayer nature of deposits occurring in Gaucher's disease. Arch Biochem Biophys 1973; 159: 259.
12. Grabowski GA, Horowitz M. Gaucher's disease: molecular, genetic and enzymologic aspects. Bailliere's Clin Haematol 1997; 10: 635.
13. Sibille A, Eng CM, Kim SJ, Pastores G, Grabowski GA. Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications. Am J Hum Genet 1993; 52: 1094.
14. Grabowski GA. Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Testing 1997; 1: 5.
15. Zimran A, Kay A, Gelbart T et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine 1992; 71: 337.
16. Grace ME, Newman KM, Scheinker V, He G, Berg-Fussman A, Grabowski GA. Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression. J Biol Chem 1994; 269: 2283.
17. Grace ME, Berg A, He GS, Goldberg L, Horowitz M, Grabowski GA. Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes. Am J Hum Genet 1991; 49: 646.
18. Ohashi T, Hong CM, Weiler S et al. Characterization of human glucocerebrosidase from different mutant alleles. J Biol Chem 1991; 266: 3661.
19. Bergmann JE, Grabowski GA. Post-translational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts. Am J Hum Genet 1989; 44: 741.
20. Jonsson LM, Murray GJ, Sorrel SH et al. Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. Eur J Biochem 1987; 164: 171.
21. Berg-Fussman A, Grace ME, loannou Y, Grabowski GA. Human beta-glucosidase: N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J Biol Chem 1993; 268: 14861.
22. Takasaki S, Murray GJ, Furbish FS, Brady RO. Barranger JA, Kobata A. Structure of the N-asparagine-linked oligosaccharide units of human placental β-glucocerebrosidase. J Biol Chem 1984; 259: 10112.
23. Imai K. Characterization of beta-glucosidase as a peripheral enzyme of lysosomal membranes from mouse liver and purification. J Biochem (Tokyo) 1985; 98: 1405.
24. Christomanou H, Aignesberger A, Linke RP. Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. Biol Chem Hoppe Seyler 1986; 367: 879.
25. Christomanou H, Chabäs A, Pämpols T, Guardiola A. Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder. Klin Wochenschr 1989; 67: 999.
26. Xu Y, Ponce E, Sun Y et al. Tissue distribution and half-lifes of intravenously administered alglucerase. Pediatr Res 1996; 39: 313.
27. Stahl PD, Rodman JS, Miller MJ, Schlesinger PH. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc Natl Acad Sci USA 1978; 75: 1399.
28. Ezekowitz AB, Sastry K, Bailly P, Warner A. Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med 1990; 172: 1785.
29. Wu K, Yuan J, Lasky LA. Characterization of a novel member of the macrophage mannose receptor type C lectin family. J Biol Chem 1996; 271: 21323.
30. Taylor ME. Evolution of a family of receptors containing multiple C-type carbohydrate-recognition domains. Glycobiology 1997; 7: v-xv.
31. 2+ and monosaccharide binding to a C-type carbohydrate-recognition domain of the macrophage mannose receptor. J Biol Chem 1997; 272: 5668.
32. Pontow SE, Kery V, Stahl PD. Mannose receptor. Int Rev Cytol 1997; 137: 221.
33. 4-4-GalNAcβ1,4GlcNAcβ or Man at independent sites. Proc Natl Acad Sci USA 1997; 94: 11256.
34. Pontow SE, Blum JS, Stahl PD. Delayed activation of the mannose receptor following synthesis. J Biol Chem 1996; 271: 30736.
35. Lennartz MR, Cole FS, Stahl PD. Biosynthesis and processing of the mannose receptor in human macrophages. J Biol Chem 1989; 264: 2385.
36. Wileman TE, Lennartz MR, Stahl PD. Identification of the macrophage mannose receptor as a 175 kDa membrane protein. Proc Natl Acad Sci USA 1986; 83: 2501.
37. Asumendi A, Alvarez A, Martinez I, Smedsrod B, VidalVanaclocha F. Hepatic sinusoidal endothelium heterogeneity with respect to mannose receptor activity is interleukin-1 dependent. Hepatology 1996; 23: 1521.
38. Eichbaum Q, Heney D, Chung M, Davidson M, Epstein J, Ezekowitz AB. Murine macrophage mannose receptor promoter is regulated by the transcription factors PU. 1 and Spl. Blood 1997; 90: 4135.
39. Hubbard AL, Wilson G, Ashwell G, Stukenbrok H. An electron microscope autoradiographic study of the carbohydrate recognition systems in rat liver. J Cell Biol 1979; 83: 47.
40. Hubbard AL, Stukenbrok H. An electron microscope autoradiographic study of the carbohydrate recognition systems in rat liver. J Cell Biol 1979; 83: 65.
41. Achord DT, Brot FE, Bell CE, Sly WS. Human betaglucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 1978; 15: 269.
42. Furbish FS, Steer CJ, Krett NL, Barranger JA. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta 1981; 673: 425.
43. Furbish FS, Steer CJ, Barranger JA, Jones EA, Brady RO. The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells. Biochemical & Biophysical Research Communications 1978; 81: 1047.
44. Murray GJ, Oliver KL, Jin F, Brady RO. Studies on the turnover of exogenous mannose-terminal glucocerebrosidase in rat liver lysosomes. J Cell Biochem 1995; 57: 208.
45. Praaning-van Dalen DP, de Leeuw AM, Brouwer A, Knock DL. Rat liver endothelial cells have a greater capacity than Kupffer cells to endocytose N-acetylglucosamine- and mannose-terminated glycoproteins. Hepatology 1987; 7: 672.
46. Murray GJ, Jin F. Immunoelectron microscopic localization of mannose-terminal glucocerebrosidase in lysosomes of rat liver Kupffer cells. J Histochem Cytochem 1995; 43: 149.
47. Willemsen R, Tibbe JJ, Kroos M, Reuser A, Ginns E. A biochemical and immunocytochemical study on the targeting of alglucerase in murine liver. Histochem J 1995; 27: 639.
48. Mistry PK, Wraight EP, Cox TM. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet 1996; 348: 1555.
49. Sato Y, Beutler E. Binding, internalization and degradation of mannose-terminated glucocerebrosidase by macrophages. J Clin Invest 1993; 91: 1909.
50. Pastures GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1 : dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993; 82: 408.
51. Fallet S, Grace ME, Sibille A et al. Enzyme augmentation in moderate to life-threatening Gaucher disease. Pediatr Res 1992; 31: 496.
52. Grabowski GA, Barton NW, Pastores G et al. Enzyme therapy in Gaucher disease type 1 : comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122: 33.
53. Figueroa ML, Rosenbloom BE, Kay A et al. A less costly regimen of alglucerase to treat Gaucher's disease. N Engl J Med 1992; 327: 1632.
54. Beutler E, Kay A, Saven A et al. Enzyme replacement therapy for Gaucher disease. Blood 1991; 78: 1183.
55. Zimran A, Elstein D, Levy-Lahad E, Zevin S. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995; 345: 1479.
56. Zimran A, Elstein D, Kannai R et al. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype and clinical features on response to treatment. Am J Med 1994; 97: 3.
57. Hollak CE, Aerts JM, Goudsmit R et al. Individualized low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 1995; 345: 1474.
58. Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324: 1464.
59. Ludwig J. Current methods of autopsy practice. Philadelphia: W.B. Saunders, 1979.
60. Barton DJ, Ludman MD, Benkov K, Grabowski GA, LeLeiko NS. Resting energy expenditure in Gaucher's disease type 1 : effect of Gaucher's cell burden on energy requirements. Metabolism 1989; 38: 1238.
61. ol.Moscicki RA. Dosage regimens of alglucerase in Gaucher disease: a comparison of the rate and extent of clinical response. ICGG Regis Update 1: August 1995.
62. Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine (Baltimore) 1985; 64: 310.
63. Hermann G, Goldblatt J, Levy RN, Goldsmith SJ, Desnick RJ, Grabowski GA. Gaucher's disease type 1: assessment of bone involvement by CT and scintigraphy. Am J Roentgenol 1986; 147: 943.
64. Beighton P, Goldblatt J, Sacks S. Bone involvement in Gaucher disease. Prog Clin Biol Res 1982; 95: 107.
65. Goldblatt J, Sacks S, Beighton P. The orthopedic aspects of Gaucher disease. Clin Orthop 1978; 208.
66. Myers HS, Cremin BJ, Beighton P, Sacks S. Chronic Gaucher's disease: radiological findings in 17 South African cases. Br J Radiol 1975; 48: 465.
67. Rosenthal DI, Scott JA, Barranger J et al. Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg [Am] 1986; 68: 802.
68. Cremin BJ, Davey H, Goldblatt J. Skeletal complications of type I Gaucher disease: the magnetic resonance features. Clin Radiol 1990; 41: 244.
69. Goldblatt J, Beighton P. South African variants of Gaucher disease. Prog Clin Biol Res 1982; 95: 95.
70. Amstutz HC. The hip in Gaucher's disease. Clin Orthop 1973: 90: 83.
71. Draznin SZ, Singer K. Legg-Perthes' disease: a syndrome of many etiologies? With clinical and roentgenographic findings in a case of Gaucher's disease. Am J Roentgenol 1948; 60: 490.
72. Billings AA, Post M, Shapiro CM. Febrile reaction of Gaucher's disease. III. Med J 1973; 144: 222.
73. Siffert RS, Platt A. Gaucher's disease: orthopaedic considerations. Prog Clin Biol Res 1982; 95: 617.
74. Bildman B. Martinez M Jr., Robinson LH. Gaucher's disease discovered by mandibular biopsy: report of case. J Oral Surg 1972; 30: 510.
75. Frederickson DS, Sloan HR. Glucosyl ceramide lipidoses: Gaucher's disease. In: Stanbury JB, Wyngaarden JB, Frederickson DS (eds). The Metabolic Basis of Inherited Disease. New York: McGraw-Hill. 1978; 730.
76. Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine 1985; 64: 310.
77. Ostlere L, Warner T, Meunier PJ et al. Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate). Q J Med 1991; 79: 503.
78. Allen MJ, Myer BJ, Khokher AM. Rushton N, Cox TM. Proinflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM 1997; 90: 19.
79. Gery I, Zigler JS Jr., Brady RO, Barranger JA. Selective effects of glucocerebroside (Gaucher's storage material) on macrophage cultures. J Clin Invest 1981; 68: 1182.
80. Ohshima T, Sasaki M. Matsuzaka T, Sakuragawa N. A novel splicing abnormality in a Japanese patient with Gaucher's disease. Hum Mol Genet 1993; 2: 1497.
81. Pastores G, Wallenstein S, Desnick RJ, Luckey MM. Bone density in type 1 Gaucher disease. J Bone Min Res 1997; 11: 1801.
82. Pastores G, Sibille A, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993; 82: 408.
83. Beutler E, Demina A. Laubscher K et al. The clinical course of treated and untreated Gaucher disease: a study of 45 patients. BCMD 1995; 21: 86.
84. Elstein D, Hadas-Halpern I, Itzchaki M, Lahad A. Abrahamov A, Zimran A. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. BCMD 1996; 22: 101.
85. Rosenthal DI, Doppelt SH, Mankin HJ et al. Enzyme replacement therapy for Gaucher disease: skeletal response to macrophage-targeted glucocerebrosidase. Pediatrics 1995; 96: 629.
86. O'Rourke NP, McCloskey EV. Kanis JA. Tumour induced hypercalcaemia: a case for active treatment. Clinical Oncology (Royal College of Radiologists) 1994; 6: 172.
87. Fleisch H. Bisphosphonates: mechanisms of action and clinical use. In: Bilezikian JP, Raisz LG, Rodan GA (eds). Principles of Bone Biology. New York: Academic Press, 1996; 1037.
88. Adami S, Mian M, Gatti P et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 1994; 15: 415.
89. Reid IR, Nicholson GC, Weinstein RS et al. Biochemical and radiologie improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial [see comments]. American Journal of Medicine 1996; 101: 341.
90. Chesnut CH, McClung MR, Ensrud KE et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144.
91. Liberman UA, Weiss SP, Broil J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437.
92. Goldman AB, Jacobs B. Femoral neck fractures complicating Gaucher disease in children. Skeletal Radiol 1984; 12: 162.
93. Kaplan P, Mazur A, Manor O et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996; 129: 149.
94. Zimran A, Hadas-Halpern I, Zevin S, Levy-Lahad E, Abrahamov A. Low-dose high frequency enzyme replacement therapy for very young children with severe Gaucher disease. Br J Haematol 1993; 85: 783.
95. Prows CA, Sanchez N, Daugherty C, Grabowski GA. Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet 1997; 71: 16.
96. Bove K, Daughtery C, Grabowski GA. Pathologic findings in Gaucher disease type 2 patients following enzyme therapy. Hum Pathol 1995; 26: 1040.
97. Schiffman R, Heyes MP, Aerts JM et al. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Ann Neurol 1997; 42: 613.
98. Lee RE. The pathology of Gaucher disease. Prog Clin Biol Res 1982; 95: 177.
99. Ponce E, Moskovitz J, Grabowski GA. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid β-glucosidase. Blood 1997; 90: 43.
100. Brady RO, Murray GJ, Oliver KL et al. Management of neutralizing antibody to ceredase in a patient with type 3 Gaucher disease. Pediatrics 1998; 100: in press.